Abstract Background: The aim was to determine the efficacy of heart-type fatty acid-binding protein (H-FABP) compared with routinely myoglobin (MYO), creatine kinase-MB (CK-MB) and cardiac troponin-I (cTn-I) in the early diagnosis of acute myocardial infarction (AMI) in patients presenting with acute chest pain. Methods and results: The patients were classified as AMI (n = 22), unstable angina (UA, n = 20) and non-cardiac chest pain (NCCP, n = 15) within 3 h and 6 h of acute chest pain according to the American College/European Society of Cardiology; and normal healthy subjects (controls, n = 10). Blood H-FABP levels were measured by ELISA and compared with cTn-I, CK-MB and MYO in all subjects. The diagnostic sensitivity, specificity and receiver operating characteristic (ROC) curve were evaluated. Serum H-FABP, MYO, CK-MB and cTn-I were significantly higher in AMI more than the UA, NCCP (non-AMI) and control groups within 6 h. However, Serum H-FABP, MYO and CK-MB were significantly elevated within 0-3 h and extend more within 3-6 h in AMI versus non-AMI. The cutoff value of H-FABP in AMI was 21.85 ng/ml within 3 h, and has diagnostic sensitivity (81.8%) equal to that of CK-MB and cTn-I but superior to that of MYO (72.7%). However, H-FABP has higher specificity (88.2%) equal to that of MYO but superior to that of CK-MB and cTn-I. This trend extends to within 6 h as well. Moreover, ROC curve areas for H-FABP were significantly higher (p < 0.05) than other biomarkers <6 h after the onset of chest pain. Conclusion: H-FABP can be used as a sensitive biomarker for myocardial injury in early stage.
Introduction
Major causes of acute chest pain include cardiac, gastro-esophageal, musculoskeletal and pulmonary conditions. 1 Forty percent (40%) of patients presenting with acute chest pain could be spared the risks and costs of unnecessary hospital admission and more invasive cardiac testing by simply adding test to the diagnostic protocol to rule out heart attack. 2, 3 Identification and management or excluding of patients with acute chest pain due to acute myocardial infarction (AMI) is a common and difficult challenge for emergency physicians. 4, 5 Thus, early AMI diagnosis relies crucially on the cardiac biochemical markers in these cases. 2 Old biochemical markers were used as AMI indicators such as serum aspartate transaminase (AST) and lactic dehydrogenase-1 (LDH-1). 6 Myoglobin (MYO), creatine kinase-MB (CK-MB), troponin T and I (cTn-T, cTn-I) are nowadays widely used in diagnosing patients with acute chest pain for the detection of myocardial tissue damage and also manage high-risk patients. [7] [8] [9] However, they do not possess high diagnostic sensitivity or specificity for AMI in early stage, especially within 3 h after onset of persistent angina pectoris. 9, 10 Recently, another cardiac biomarkers such as glycogen phosphorylase BB (GP-BB) and carbonic anhydrase III (CA-III) were assessed, 7, 11 but until now, the ideal marker is not present.
Recently, Heart-type fatty acid binding protein (H-FABP) is about 10-fold lower in skeletal muscle than that in heart muscle, and the amounts in the kidney, liver, small intestine, brain, lactating mammary glands and the placenta are even lower. 9 H-FABP can be transported from severely damaged cardiomyocytes to the blood more rapidly than other markers such as MYO, cTn-I and CK-MB. 12 MYO is more sensitive in the early phase of AMI, but its specificity is not satisfying. H-FABP as a marker of myocardial ischemia even in the absence of frank necrosis, and may be a useful tool as prognostic value of elevated H-FABP for monitoring of a recurrent infarction. 4 H-FABP may be useful in low and intermediate risk patients with suspected acute coronary syndrome with negative troponins. 12 The magnitude of the increase in plasma H-FABP has also demonstrated a good correlation with the size of the infarction. 6 In the clinical studies, serum H-FABP level is also elevated under hypertrophic and dilated cardiomyopathy, heart failure, hypertension, aortic valve regurgitation and pulmonary embolism. 6 H-FABP might have potential as an early cardiac biomarker, although the clinical impact of this better diagnostic performance remains unclear. 13 Therefore, the aim of this study was to determine the efficacy of H-FABP compared with routinely MYO, cTn-I and CK-MB in the early diagnosis of AMI in patients presenting with acute chest pain in emergency room. Also, H-FABP can differentiate between cardiac and non-cardiac acute chest pain.
Subjects and methods

Study subjects
This study was carried out on 67 subjects: 57 patients and 10 healthy subjects (controls). The patients were selected from Intensive Care Unit, Cardiology Department, Menoufiya University Hospital between November 2009 and May 2010. The protocol of this study was approved by the local ethics committee, Faculty of Medicine, Menoufiya University; and written informed consent was obtained from every subject participating in this study.
Patients presenting with acute chest pain more than 30 min and less than 6 h suspected of AMI, unstable angina and noncardiac chest pain were enrolled consecutively in the study. These patients were also randomly classified according the time of chest pain onset into two groups (0-3 and 3-6 h). Full history taking including patients' symptoms and past medical history such as diabetes mellitus (DM), hypertension (HTN) and previous ischemic event; and general clinical examination, ECG and laboratory investigations were documented at admission using a pre-defined protocol.
Diagnostic criteria: The standard diagnosis was made after critical review of all the clinical pictures and relevant information by a senior cardiologist. AMI was defined according to the European Society of Cardiology/American College of Cardiology Committee Criteria. 5, 14 AMI was defined as detection of initial or 6 h cTn-I P 0.1 ng/ml together with evidence of myocardial ischemia with at least one of the following: (i) symptoms of ischemia; (ii) ECG changes indicative of new ischemia (new ST-T changes or new left bundle branch block [LBBB]); (iii) development of pathological Q waves in the ECG; (iv) imaging evidence of new loss of viable myocardium or new regional wall motion abnormality. Diagnostic outcomes were first categorized into the following groups: (i) ST-elevation myocardial infarction (STEMI); (ii) non-ST-elevation myocardial infarction (NSTEMI); (iii) unstable angina (UA); and (iv) non-cardiac chest pain (NCCP). The first two groups were later integrated into AMI group, and the last two into non-myocardial infarction (non-AMI) group. Controls were selected on the basis of healthy condition without cardiovascular diseases, lung and kidney diseases, with normal blood pressure and electrocardiogram, normal serum lipids and normal blood glucose.
N.B: In this study, NCCP patients included chest wall diseases and trauma, gall bladder stones, gastritis, peptic ulcer, pulmonary embolism, pleuritis, psychic, bronchial asthma, mitral valve prolapse and reflux oseophagitis.
Exclusion criteria: Patients with one of the following criteria are excluded: arrival to the hospital over 6 h after the onset of chest pain; patients who underwent percutaneous transluminal coronary angioplasty or coronary artery bypass grafting within 30 days; patients who had prior AMI within 30 days; having chronic muscle disease; receiving direct current (DC) shock; renal insufficiency or any renal disease impairing renal clearance; and recent surgery (cardiac and non-cardiac).
Laboratory analysis
Only one venous blood sample (10 ml) was withdrawn by sterile venous puncture and clean dry syringes from the cubital vein of every investigated subject at the time of admission to the hospital within 6 h after the onset of symptoms. Blood serum was separated from the clot and liquated under complete aseptic condition. The serum obtained was kept frozen at À20°C till the analysis of serum AST, ALT, total cholesterol, triglyceride, creatinine, cTn-I, CK-MB, MYO and H-FABP.
Myoglobin (MYO) was determined by enzyme linked immunosorbent assay (ELISA, DRG International Inc., USA). This assay system utilizes a unique monoclonal antibody directed against a distinct antigenic determinant on the myoglobin molecule such as mouse monoclonal anti-myoglobin antibody. Also, the assay for measuring cTn-I (Enzyme-Linked Fluorescent Assay, ELFA, BioMerieux Inc., USA) and CK-MB (enzyme linked immunosorbent assay, ELISA, Oxis International Inc., USA) in routine clinical practice at our recruiting hospital was upgraded partway through the study. However, cTn-I and CK-MB value used in routine clinical practice for monitoring patients as having had an acute MI was effectively positive throughout the study period.
The H-FABP was determined by enzyme linked immunosorbent assay (ELISA, Biocheck Inc., USA). The assay system utilizes an affinity purified goat anti-H-FABP antibody. H-FABP kit was applied to qualitatively determine the H-FABP levels in blood samples with a cut-off level at >19 ng/ml. MYO, cTn-I and CK-MB were determined with cut-off levels of 85 ng/ml, 0.11 lg/l, and 5.2 ng/ml respectively.
Any results that were equal or more the cut-off levels were defined as positive results. Conversely, those being less than the cut-off levels were defined as negative results. Regarding the combinations, positive results were defined as positive of any component markers, while negative results were defined as negative of all the component markers.
Statistical analysis
Results were statistically analyzed by IBM personal computer and statistical package SPSS version 11. Mean ± standard deviation (SD), percentage (%), Student's t test and MannWhitney test (non-parametric test) were used in the assessment of AMI and non-AMI groups. Chi-square (v 2 ) test, sensitivity, specificity, positive and negative predictive values, diagnostic accuracy and ROC (receiver operating characteristic) curve were used to assess the diagnostic validity of H-FABP, CK-MB, MYO and cTn-I. Multiple groups' comparison was made by the non-parametric Kruskall and Wallace test and paired comparisons were made by Wilcoxon rank test. Results are given as mean ± SD, cut-off values according to sample times (95% confidence interval, CI). P values < 0.05 were considered statistically significant.
Results
Sixty-seven subjects were enrolled in the study and divided into four groups: Group 1: Acute myocardial infarction (AMI) patients (n = 22, 18 males and 4 females). Their ages were ranged between 35 and 76 years with mean 58.0 ± 10.65 years. Group 2: Unstable angina (UA) patients (n = 20, 16 males and 4 females). Their ages were ranged between 27 and 74 years with mean 56.10 ± 9.30 years. Group 3: Non-cardiac chest pain (NCCP) patients (n =
Incidence of smoking, history of DM and hypertension were significantly higher in AMI than the control groups. Incidence of smoking and hypertension was significantly higher in UA than the control groups. All parameters in AMI group were significantly higher than those in the non-AMI (UA and NCCP) and control groups within 6 h (see Table 1 ) Serum H-FABP, MYO and CK-MB were significantly increased in 0-3 h with more increased in 3-6 h after chest pain of AMI. Whereas, serum cTn-I was non-significant increased in Fig. 1 . The diagnostic sensitivity and specificity of cut-off values and area under the ROC curves for H-FABP, MYO, cTn-I and CK-MB are shown in Table 2 . H-FABP possessed higher sensitivity than that of cTn-I and CK-MB at all time points after the onset of symptoms. The sensitivity of H-FABP within 3 h was 81.8% and reached 100% within 3-6 h. H-FABP has higher sensitivity than MYO within 3 h. The specificity data for non-AMI were significantly higher among the H-FABP and MYO at all time points after the onset of symptoms. The overall specificity within 3-6 h was 88.9% for H-FABP and equal to MYO but, 77.8% for cTn-I, 94.9% for CK-MB. Also, the areas under the ROC curves of H-FABP and MYO in the AMI group were significantly higher (p < 0.05) than other biomarkers in the non-AMI group at 3 h and 6 h in Table 2 . The data from ROC analysis are summarized in Fig. 2 ; ROC curves were constructed by plotting the sensitivity for the confirmed AMI group (n = 22) on the Y-axis and 1-specificity for the non-AMI group (n = 35) on the X-axis within 3 h and 6 h after the onset of chest pain.
Discussion
AMI is the main cause of mortality and disability in the modern world. Early and correct diagnosis is of great importance to enable immediate and intensified treatment which consequently reduces mortality . 9 If treatment of AMI is done within 1 h (the golden hour) effectively, mortality can be reduced from 9% to 3%, if delay of 3-4 h, mortality could be five times higher. 4 However, the golden moment for optimal outcome of coronary revascularization is within 4 h after the onset of occlusive coronary thrombosis so early diagnosis is important for cardiac etiology in patients presenting with acute chest pain. 8 Unfortunately, at least one-fifth of AMI is clinically unrecognized because of the absence of chest discomfort or atypical ECG changes. 15, 16 Early diagnosis of AMI has great clinical significance, because the duration of symptoms has a strong impact on the hospital management strategy. 2 Our goal will require altering the current methods of cardiac biomarkers for identifying such patients.
The heart is a poor fatty acid synthesizer, and contributes only 0.1% of total body fatty-acid synthesis, but accounts for 10% of the total body turnover of fatty acids. H-FABP may constitute the intracellular equivalent of albumin for the intracellular transport of the insoluble fatty acids within the myocytes. 6 The protective role for H-FABP, as scavengers of free radicals 17 and against detergent-like effects of locally high concentrations of long-chain fatty acids 18 , particularly during cardiac ischemia. 12 Our study showed that H-FABP has greater diagnostic value in patients with suspected AMI than does cTn-I, CK-MB or MYO within 3 h following onset of acute chest pain rather than at a later 6 h. These results were similar to other published previously. 4, 9, 10, 19 Consequently, H-FABP concentrations have a greater predictive capacity for cardiac events than cardiac troponin within 3 h of the onset of chest pain. Conflicting results about cardiac markers may be explained by the duration of AMI at the time of sampling or other factors in AMI studies. 20 H-FABP appears in plasma 1-3 h with peak at 6 h after cardiac damage, and may be the earliest available plasma marker of acute myocardial injury and returns to normal values in 12-24 h. 15 However, CK-MB begins to increase between 3 and 5 h after the onset of infarction and peaking at 16-20 h.
11 CK-MB is not perfectly specific to cardiac injury as it increases during massive musculo-skeletal injury. 19 Moreover, MYO lacks specificity because it is released from skeletal muscles and cannot be distinguished from that released from the heart. 21 The superior performance of H-FABP may be attributed to the following two factors: (i) smaller molecular weight: H-FABP is a small cytoplasmic protein, which has a very low molecular weight of 15 kDa, while the molecular weights of MYO, cTn-I and CK-MB are 18, 22.5 and 80 kDa respectively 13 ; (ii) steeper tissue-to-plasma gradient: The myocardial content of H-FABP (0.52 mg/g wet wt) is 4.5-fold lower than that of MYO (2.35 mg/g wet wt), yet the basic plasma level of H-FABP (2.8 lg/l) is 10-fold lower than the later (30 lg/ l). 15, 21 So H-FABP tissue-to-plasma gradient is at least twofold steeper than that of MYO. This characteristic, along with the higher permeability of the endothelial barrier for small proteins, enable H-FABP to exhibit an early and significant release after myocardial injury with or without necrosis and make it more easily being detected. The presence of myocardial ischemia resulting in chest pain might result from coronary spasm in the presence of atheroma but in the absence of plaque erosion/rupture and thrombus formation. Such patients might be expected to have no detectable troponins and yet have an elevated H-FABP and, importantly, an increased risk of future major cardiovascular event.
Our data demonstrate that the cut off value of H-FABP for the diagnosis of AMI from cases of acute chest pain within 3 h of onset was 21.85 ng/ml and H-FABP has sensitivity equal to that of CK-MB and superior to that of MYO. This trend extends to the 6 h of myocardial injury as well. This result is confirmed by other studies. [22] [23] [24] [25] However, the specificity of MYO and H-FABP was the same percentage value but more superior than cTn-I and CK-MB which was similar to other study. 19, 26, 27 The current study showed that acute chest pain within 0-3 h, the areas under the ROC curve for H-FABP and MYO in the AMI group were highly significant than in the non-AMI group which was similar to that reported in multicenter EUROCARDI trials 27 and other study. 19 This study showed that the cut off value of H-FABP for the diagnosis of AMI from cases of acute chest pain within 3-6 h of onset was 31.45 ng/ml. At this cut off value, the sensitivity was 100% and equal to that of the MYO, However, the specificity of H-FABP was 88.9% which is equal to MYO and higher than cTn-I but, lower than that of CK-MB. These results were similar to that reported in other publications. 9, 19 Conclusion: H-FABP can detect early myocardial injury (infarction) and can exclude other acute non-cardiac chest pain causes within 3 h. H-FABP can be useful in the early diagnosis of acute chest pain in comparison with other traditional biomarkers CK-MB, cTn-I and MYO. Combining H-FABP and MYO provides the best performance for early AMI diagnosis.
Emergency departments are under increasing pressure to process patients in less time. Therefore, a test that stratifies the risk of patients with chest pain more rapidly would be valuable, facilitating earlier discharge. It is recommended to use H-FABP bedside test. It can easily be performed by drawing four drops of capillary whole blood from the patient's finger and applying them onto the test-strip within 15 min for cTn-I, CK-MB, MYO and H-FABP. 2, 4, 11 
